Gut microbe metabolite found to modulate heart disease risk through β2-adrenergic receptors

Study identifies phenylacetylglutamine (PAGln), a gut microbiome metabolite, as a novel allosteric modulator of β2-adrenergic receptors, offering insights into its role in cardiovascular disease (CVD) risk.

Long COVID unmasked: Patients share varied physical, mental, and social challenges

Patient experiences of the post-acute sequelae of coronavirus disease 2019 (COVID-19) or long COVID.

October 2, 2023

Why more Americans aren’t using the 988 mental-health crisis hotline

It’s been a year since the U.S. launched its 988 national mental health hotline — and while the service is still dealing with logistical challenges,

July 13, 2023

Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass

Featured content in this Issue: This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to

February 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.